The specter of generic competition has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the prospects of connected medicinal stakes. While early times saw substantial profits, the intellectual property expiration has allowed the way for discounted copies, possibly reducing revenue and creating a real